JPS5936630B2 - 2-imino-1,3-diazacycloalkane derivative - Google Patents
2-imino-1,3-diazacycloalkane derivativeInfo
- Publication number
- JPS5936630B2 JPS5936630B2 JP1299076A JP1299076A JPS5936630B2 JP S5936630 B2 JPS5936630 B2 JP S5936630B2 JP 1299076 A JP1299076 A JP 1299076A JP 1299076 A JP1299076 A JP 1299076A JP S5936630 B2 JPS5936630 B2 JP S5936630B2
- Authority
- JP
- Japan
- Prior art keywords
- imino
- formula
- benzhydryl
- compound
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 19
- -1 1-benzhydryl-2-imino-3-methylimidazolidine Chemical compound 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DISXFZWKRTZTRI-UHFFFAOYSA-N 4,5-dihydro-1h-imidazol-2-amine Chemical compound NC1=NCCN1 DISXFZWKRTZTRI-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- ACYBVNYNIZTUIL-UHFFFAOYSA-N n'-benzylethane-1,2-diamine Chemical compound NCCNCC1=CC=CC=C1 ACYBVNYNIZTUIL-UHFFFAOYSA-N 0.000 description 1
- RFLHDXQRFPJPRR-UHFFFAOYSA-N n'-benzylpropane-1,3-diamine Chemical compound NCCCNCC1=CC=CC=C1 RFLHDXQRFPJPRR-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【発明の詳細な説明】
本発明は一般式(1)
ら0、、ユニー」−ヘ
(式中R1は水素原子又はフェニル基を、R2及びR3
は各々独立して水素原子、低級アルキル基又は低級ヒド
ロキシアルキル基を、nは2〜4の整数を意味す。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to the general formula (1) ra0, uni'-h (wherein R1 is a hydrogen atom or a phenyl group, R2 and R3
each independently represents a hydrogen atom, a lower alkyl group or a lower hydroxyalkyl group, and n represents an integer of 2 to 4.
ただしnが2でR1、R2及びR3が水素原子のものは
除く)で示される新規化合物、2−イミノ−1・3−ジ
アザシクロアルカン誘導体又はその酸付加塩に関し、式
(1)の化合物は強力な血糖降下作用を呈する。式(1
)で示される化合物は下記の方法で製することが出来る
。However, regarding new compounds represented by (excluding those where n is 2 and R1, R2 and R3 are hydrogen atoms), 2-imino-1,3-diazacycloalkane derivatives or acid addition salts thereof, compounds of formula (1) exhibits a strong hypoglycemic effect. Formula (1
) can be produced by the following method.
(上記式中R4はシアノ基、低級アルカノイル基又は低
級アルコキシカルボニル基を、R5は低級アルキル基を
、Xはハロゲン原子を意味しR1、R2、R3及びnは
前記に同じ)即ち、5法によれば式()で表わされるア
ミン類をシアン化ハロゲンを溶解した有機溶媒中に添加
することによつて殆んど定量的に目的物が得られる。(In the above formula, R4 is a cyano group, a lower alkanoyl group or a lower alkoxycarbonyl group, R5 is a lower alkyl group, X is a halogen atom, and R1, R2, R3 and n are the same as above). According to this, the desired product can be obtained almost quantitatively by adding amines represented by the formula () to an organic solvent in which a halogen cyanide is dissolved.
この反応に於ける有機溶媒としてはメタノール、エタノ
ール等のアルコール類、クロロホルム、ベンゼン等の−
般有機溶媒が用いられ、反応温度としては室温乃至約6
0℃の範囲が好ましい。なおシアン化ハロゲンに代えグ
アニジン塩酸塩を用いる場合、溶媒を用いることなく式
()で表わされる化合物と直接120〜200℃好まし
くは160〜180℃に数時間加熱することにより目的
化合物を製することが出来る。5法によれば、目的化合
物は式()の原料化合物を例えばジメチルホルムアミド
中、水素化ナトリウム、ナトリウムアルコラード等の脱
酸剤の存在下室温乃至150℃位の温度にてハロゲン化
アルキルと反応させることにより得ることが出来る。Organic solvents used in this reaction include alcohols such as methanol and ethanol, chloroform, benzene, etc.
A general organic solvent is used, and the reaction temperature ranges from room temperature to about 6
A range of 0°C is preferred. When using guanidine hydrochloride instead of halogen cyanide, the target compound can be prepared by heating directly with the compound represented by the formula () at 120 to 200°C, preferably 160 to 180°C for several hours without using a solvent. I can do it. According to method 5, the target compound is obtained by reacting the starting compound of formula () with an alkyl halide in dimethylformamide in the presence of a deoxidizing agent such as sodium hydride or sodium alcolade at a temperature from room temperature to about 150°C. It can be obtained by letting
5法によれば、式()の化合物を第三級ブタノール中2
〜3倍モルの塩酸存在下5 〜,8時間加)Y熱するこ
とにより、目的化合物が得られる。According to method 5, a compound of formula () is dissolved in tert-butanol with 2
The target compound is obtained by heating for 5 to 8 hours in the presence of ~3 times the mole of hydrochloric acid.
又4法によれば、式(V)の原料化合物とアルキルアミ
ン類とをアルコール溶媒中数時間乃至十数時間約60〜
100℃に加熱することにより目的化合物が得られる。
かくして製される本発明の化合物は1・3−ジアザシク
ロアルカン誘導体の1位にベンジル基もしくはベンズヒ
ドリル基を有し、従来の血糖降下薬とは根本的に異なる
構造上の特異性を有するものであり、かつ強力な血糖降
下作用を有するものである。According to method 4, the raw material compound of formula (V) and the alkylamines are heated in an alcohol solvent for about 60 to more than ten hours.
The target compound is obtained by heating to 100°C.
The compound of the present invention thus produced has a benzyl group or benzhydryl group at the 1-position of the 1,3-diazacycloalkane derivative, and has structural specificity fundamentally different from that of conventional hypoglycemic drugs. and has a strong hypoglycemic effect.
更に詳しくは、本発明の化合物は正常な空腹動動におい
て従来繁用されている血糖降下薬であるスルホニル尿素
系及びビグアニド系化合物と比較検討した結果より優れ
た効果を呈する。More specifically, the compounds of the present invention exhibit superior effects on normal fasting movements compared to sulfonylurea and biguanide compounds, which are conventionally frequently used hypoglycemic drugs.
本発明化合物の数例についてその血糖降下作用を市販の
トルブタマイド及びフエンフオルミンと対比したときの
結果を下記に示す。The results of comparing the hypoglycemic effects of several examples of the compounds of the present invention with those of commercially available tolbutamide and fenformine are shown below.
実施例 1
1−ベンジルアミノ−2−アミノエタン6.0yをシア
ン化臭素4.45yのベンゼン150dの溶液の中へ攪
拌下、反応温度が50℃以上にならないように加える。Example 1 6.0 y of 1-benzylamino-2-aminoethane is added to a solution of 4.45 y of bromine cyanide in 150 d of benzene while stirring so that the reaction temperature does not rise above 50°C.
2〜4時間後析出した結晶を集めると1−ベンジル−2
−イミノイミダゾリジンの臭化水素酸塩が定量的に得ら
れる。After 2 to 4 hours, the precipitated crystals were collected and 1-benzyl-2
- Hydrobromide of iminoimidazolidine is obtained quantitatively.
融点200〜202℃。同一の方法で表2に示す化合物
を得た。Melting point: 200-202°C. The compounds shown in Table 2 were obtained in the same manner.
実施例 4
1−ベンジルアミノ−3−アミノプロパン6.56rと
グアニジン塩酸塩3.807を160〜180℃に6時
間加熱、冷後イソプロパノールとエーテル中こすつて結
晶化すると1−ベンジル−2−イミノ−1・3−ジアザ
シクロヘキサン塩酸塩が6.0r(67%)得られる。Example 4 6.56 r of 1-benzylamino-3-aminopropane and 3.807 r of guanidine hydrochloride were heated to 160-180°C for 6 hours, cooled, and crystallized by rubbing in isopropanol and ether to obtain 1-benzyl-2-imino. 6.0 r (67%) of -1,3-diazacyclohexane hydrochloride is obtained.
融点160〜164℃。実施例 5
1−ベンズヒドリル一2−イミノ−イミダゾリジン1.
0tをジメチルホルムアミド15m1に溶解し、50%
油性水素化ナトリウム0.22yを加えて1時間室温で
撹拌したのち、ヨ一化エチル0.69tを加える。Melting point: 160-164°C. Example 5 1-benzhydryl-2-imino-imidazolidine 1.
Dissolve 0t in 15ml of dimethylformamide and dilute to 50%
After adding 0.22 y of oily sodium hydride and stirring at room temperature for 1 hour, 0.69 t of ethyl iodide was added.
徐々に発泡して反応する。4時間撹拌をつづけたのち、
溶媒を減圧留去し残渣に水とクロロホルムを加えよく振
とうする。It reacts by gradually foaming. After stirring for 4 hours,
The solvent is distilled off under reduced pressure, water and chloroform are added to the residue, and the mixture is thoroughly shaken.
有機層を分取し、よく水洗後、乾燥してクロロホルムを
留去する。残渣にエタノールを加えて溶解してから濃塩
酸を加えてPH2にしたのち減圧濃縮乾固する。残渣は
アセトンを加えてこすると結晶化する。1−ベンズヒド
リル一2−イミノ−3−エチルイミダゾリジン塩酸塩が
0.367(29%)得られた。The organic layer is separated, thoroughly washed with water, dried, and chloroform is distilled off. Ethanol was added to the residue to dissolve it, concentrated hydrochloric acid was added to adjust the pH to 2, and the mixture was concentrated to dryness under reduced pressure. The residue crystallizes when rubbed with acetone. 0.367 (29%) of 1-benzhydryl-2-imino-3-ethylimidazolidine hydrochloride was obtained.
融点236〜237℃。同一の方法にて表3に示す化合
物を得た。Melting point 236-237°C. The compounds shown in Table 3 were obtained in the same manner.
実施例 10
1−ベンズヒドリル一2−シアノイミノ−1 ・3−ジ
アザシクロヘキサン0.58Vを第三級ブタノール10
m1と濃塩酸0.6m1の混液に液解し6時間加熱還流
する。Example 10 1-benzhydryl-2-cyanoimino-1 0.58 V of 3-diazacyclohexane was dissolved in tert-butanol 10
ml and 0.6 ml of concentrated hydrochloric acid and heated under reflux for 6 hours.
冷後、減圧濃縮乾固し残渣にアセトンを加え、こすると
結晶化し、1−ベンズヒドリル一 2 =イミノ−1・
3 −ジアザシクロヘキサン0.34V( 58%)
が得られた。融点218〜22℃。同様の方法で表4に
示すような式()の化合物から式(I)の化合物を得た
。After cooling, the residue was concentrated to dryness under reduced pressure, and acetone was added to the residue, which crystallized by rubbing.
3-Diazacyclohexane 0.34V (58%)
was gotten. Melting point 218-22°C. A compound of formula (I) was obtained from a compound of formula () as shown in Table 4 in a similar manner.
Claims (1)
R_3は各々独立して水素原子、低級アルキル基又は低
級ヒドロキシアルキル基を、nは2〜4の整数を意味す
。 ただしnが2でR_1、R_2及びR_3が水素原子の
ものは除く)で示される2−イミノ−1・3−ジアザシ
クロアルカン誘導体又はその酸付加塩。2 1−ベンズ
ヒドリル−2−イミノ−3−メチルイミダゾリジンであ
る特許請求の範囲第1項記載の化合物。 3 1−ベンズヒドリル−2−イミノ−3−エチルイミ
ダゾリジンである特許請求の範囲第1項記載の化合物。 4 1−ベンズヒドリル−2−メチルイミノイミダゾリ
ジンである特許請求の範囲第1項記載の化合物。[Claims] 1 General formula ▲ Numerical formula, chemical formula, table, etc. ▼ 2-imino-1,3-diazacycloalkane derivatives or their acids, where n is an integer from 2 to 4 (excluding those where n is 2 and R_1, R_2, and R_3 are hydrogen atoms) Added salt. 2. The compound according to claim 1, which is 1-benzhydryl-2-imino-3-methylimidazolidine. 3. The compound according to claim 1, which is 1-benzhydryl-2-imino-3-ethylimidazolidine. 4. The compound according to claim 1, which is 1-benzhydryl-2-methyliminoimidazolidine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1299076A JPS5936630B2 (en) | 1976-02-09 | 1976-02-09 | 2-imino-1,3-diazacycloalkane derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1299076A JPS5936630B2 (en) | 1976-02-09 | 1976-02-09 | 2-imino-1,3-diazacycloalkane derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5295666A JPS5295666A (en) | 1977-08-11 |
| JPS5936630B2 true JPS5936630B2 (en) | 1984-09-05 |
Family
ID=11820635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1299076A Expired JPS5936630B2 (en) | 1976-02-09 | 1976-02-09 | 2-imino-1,3-diazacycloalkane derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5936630B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63212233A (en) * | 1987-02-28 | 1988-09-05 | Fujitsu Ltd | Alarming circuit |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2773560B1 (en) * | 1998-01-14 | 2000-04-07 | Lipha | TRIAZEPINONES, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THERAPEUTICS |
| EP1176141A4 (en) * | 1999-03-05 | 2002-08-14 | Suntory Ltd | HETEROCYCLIC COMPOUNDS HAVING RECEPTOR ACTIVATION EFFECT $ g (a) 4 $ g (b) 2 OF NICOTINIC ACETYLCHOLINE |
-
1976
- 1976-02-09 JP JP1299076A patent/JPS5936630B2/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63212233A (en) * | 1987-02-28 | 1988-09-05 | Fujitsu Ltd | Alarming circuit |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5295666A (en) | 1977-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6252742B2 (en) | ||
| JP2556722B2 (en) | Novel sulfonamide compound | |
| JPS5943459B2 (en) | N-alkylpiperidine derivative | |
| JPS5921862B2 (en) | Esterification method | |
| JPS5936630B2 (en) | 2-imino-1,3-diazacycloalkane derivative | |
| US3996278A (en) | Novel 2-aminomethyl-4-,6-dihalogenphenol derivatives and methods for the preparation thereof | |
| JPS6284083A (en) | N-alkylation of dihydrolysergic acid | |
| SU492076A3 (en) | Method for producing substituted guanidine | |
| US2528940A (en) | Pyrrolidylethyl indole compounds | |
| US2793212A (en) | Substituted benzamidopiperidinopropanes | |
| JPH09169747A (en) | Novel substituted phenylthiazolidine-2,4-dione derivative and process for producing the same | |
| JPS5946511B2 (en) | 1-(N-hydroxyalkylcarbamoyl)-5-fluorouracils and their production method | |
| JPS62108867A (en) | Production of imidazolyl-methane derivative | |
| JPS6327339B2 (en) | ||
| JPS5888379A (en) | Manufacture of d-2-substituted-6-alkyl-8- substituted ergoline and related compounds | |
| JPS603062B2 (en) | Method for producing 8-hydroxycarbostyryl derivative | |
| JPS6257620B2 (en) | ||
| US3312700A (en) | Pyrazineacetonitriles and methods of preparing | |
| JPS6257618B2 (en) | ||
| JPS604830B2 (en) | Phenyl acetic acid derivative | |
| JPS5914036B2 (en) | New method for producing rifamycin SV derivatives | |
| JPS5849547B2 (en) | Pyrazoline pyrazoline | |
| JPH0479343B2 (en) | ||
| JPS607624B2 (en) | 1-(N-aralkylcarbamoyl)-5-fluorouracils and their production method | |
| JPS596865B2 (en) | 5-((2-halogeno-1-hydroxy)alkyl) carbostyril |